1. Australia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
IDT Australia Limited

IDT Australia Limited

IDT.AX
IDT Australia LimitedAU flagAustralian Securities Exchange
0.04
AUD
- -
- -
15.81MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.22
0.18
0.11
0.08
0.04
0.05
0.05
0.06
0.07
0.05
0.03
0.04
0.04
Basic EPS, GAAP
-0.11
-0.09
-0.02
-0.02
- -
-0.07
-0.02
-0.01
0.01
- -
-0.03
-0.02
-0.02
Free Cash Flow per Basic Share
-0.04
-0.03
-0.13
-0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.47
0.31
0.25
0.18
0.17
0.11
0.08
0.07
0.08
0.07
0.05
0.03
0.02
Tangible Book Value per Share
0.54
0.36
0.28
0.1
0.12
0.12
0.1
0.09
0.11
0.11
0.1
0.07
0.05
Basic Weighted Avg Shares
48
72
141
214
254
254
246
243
246
247
251
348
427
Sales/Revenue/Turnover
11
13
16
17
9
13
12
14
16
12
7
13
19
Operating Margin (%)
-44.96
-46.57
-20.26
-33.76
-79.78
-37.71
-48.92
-9.3
0.41
-15.7
-142.36
-51.8
-41.36
Depreciation Expense
3
2
2
2
2
3
3
2
2
2
1
1
1
Net Income, GAAP
-5
-7
-3
-4
-1
-17
-6
-2
2
-1
-8
-5
-8
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-50.54
-50.31
-19.05
-23.74
-8.32
-131.7
-51.2
-13.61
13.12
-9.58
-122.54
-40.93
-41.96
Working Capital
-3
3
1
2
14
14
9
9
11
11
6
3
10
LT Debt
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
10
Total Equity
26
26
39
43
49
32
25
23
28
27
24
23
22
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-21.75
-29.61
-10.43
-10.76
-1.86
-47.58
-26.08
-10.37
11.31
-6.08
-53.35
-44.93
-81.13

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-4.38%
-0.76%
-6.63%
Free Cash Flow
-51.27%
24%
87.32%
Net Income, GAAP
219.76%
56.1%
48.96%
Sales/Revenue/Turnover
9.46%
16.5%
45.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
7
2024
- -
- -
- -
- -
13
2025
- -
- -
- -
- -
19

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jim Sosic
Full Time Employees
156
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
45 Wadhurst Drive Boronia VIC Australia 3155
IPO Date
Apr 1, 1988
Website
en.idtaus.com.au
Similar Companies
Virtual Medical International, Inc. (QEBR)
BioGaia AB (publ) (BIOGY)
Faes Farma, S.A. (FAE.MC)
Captor Capital Corp. (CPTR.CN)
Crescita Therapeutics Inc. (CTX.TO)
Supernus Pharmaceuticals, Inc. (0LB2.L)
Business
IDT Australia Limited (ASX:IDT) manufactures active pharmaceutical ingredients and finished dosage forms as a contract development and manufacturing organization based in Boronia, Victoria, Australia. Founded in 1975, the company provides cGMP-compliant production of APIs from milligram to 1000-kilogram scale, including high-potency and high-containment molecules such as cytotoxics, beta-lactams, antibiotics, and intermediates for international shipment; finished oral dosage forms encompassing tablets, capsules, and non-sterile liquids; sterile injectables including lyophilized products; medicinal cannabis processing and extraction on tonnage scale with conversion to finished forms; advanced therapies like mRNA development and Antibody Drug Conjugates; analytical method development, stability testing, microbiology and chemistry quality control; clinical packaging, pharmacy services, project management, regulatory affairs, and full-scale pharmaceutical development across all dosage forms. IDT Australia operates a 12,000 square meter facility supporting projects from preclinical pilot stages through commercial supply for pharmaceutical companies, researchers, governments, and partners targeting illnesses including cancer, heart disease, diabetes, mental health conditions, and Alzheimer's, with distribution in Australia, Asia, Europe, and the United States. Recent developments include a July 2025 memorandum of understanding with NASDAQ-listed Gelteq Limited to establish a dedicated manufacturing facility for gel-based oral delivery products targeting nutraceutical, pharmaceutical, and animal health markets; a five-year $3.2 million contract awarded in April 2025 by Nacuity Pharmaceuticals for cGMP production of NPI-001 API and one million tablets as an investigational treatment for retinitis pigmentosa, supporting recommissioning of its largest small molecule API plant; full-year 2025 revenue growth of 41% to $19.9 million driven by commercial contracts across API, specialty orals, and advanced therapies; resignation of CEO Paul McDonald in August 2025 with an ongoing search for a replacement amid a strategic review to restore profitability; and settlement of a loan facility with ScotPac in January 2025 alongside quarterly revenue increases.